• Home
• Products
  • UV Phototherapy
  • Derma 308
  • MED/MPD Tester
• Order
• FAQ
  • UV Phototherapy
  • Viedo
  • Instruction
  • Real stories
• Membership
• Contact
•  
• KERNEL
  • KERNEL Website
  • Colposcope
  • Photodynamic therapy
  • Patient monitor

Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis.

Ryan C1, Renfro L, Collins P, Kirby B, Rogers S.

Author information

Abstract

BACKGROUND:

There is considerable variability in the number of exposures of narrowband ultraviolet B (NB-UVB) needed to clear psoriasis and in the duration of remission.

OBJECTIVES:

We assessed clinical parameters as predictors of the number of exposures needed to clear psoriasis and of the duration of remission. The influence of genetic polymorphisms of the vitamin D receptor (VDR) on treatment response was also evaluated.

METHODS:

This was a prospective study of 119 patients with chronic plaque psoriasis treated with NB-UVB until clearance was achieved. They were then followed for up to 1 year or until relapse occurred. The frequency of the Fok1, Apa1, Bsm1, Taq1 and rs4516035 polymorphisms of the VDR gene was assessed in 93 of the 119 patients.

RESULTS:

Of the 119 patients, 105 completed the course of phototherapy. Using an intention to treat analysis, 83% of the initial cohort (99 of 119 patients) achieved clearance, in a median of 26 exposures (interquartile range 19-35) with a median remission duration of 16 weeks (interquartile range 9-22). Factors significantly associated with a lower number of exposures to clearance included a lower baseline Psoriasis Area and Severity Index (P = 0��004), lower baseline Dermatology Life Quality Index (P = 0��047), female sex (P = 0��043), lower body weight (P = 0��008), and a higher number of previous courses of TL-01 (P = 0��005). The only clinical factor influencing remission duration was number of exposures (P = 0��0009), with a decreased remission duration in those who required a greater number of exposures to clear. The Taq1 VDR polymorphism (rs731236) also significantly predicted remission duration (P = 0��038). Patients homozygous for the C allele, which is associated with decreased activity of the VDR, had a shorter remission duration than those heterozygous for the allele (P = 0��026) and those homozygous for the T allele (P = 0��013).

CONCLUSIONS:

This study highlights the fact that both genetic and clinical parameters are important in determining treatment outcomes in psoriasis.

www.kerneluvb.com----The leader manufacturer of UV Phototherapy.